Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind Placebo-controlled Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms of Allergic Rhinitis in Response to Cat Dander Challenge

NCT06069063 is registered in ClinicalTrials.gov with Allergy & Asthma Medical Group & Research Center as lead sponsor.

NCT NCT06069063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06069063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind Placebo-controlled Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms of Allergic Rhinitis in Response to Cat Dander Challenge
Lead sponsor
Allergy & Asthma Medical Group & Research Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 5, 2025
Completion date
July 31, 2026
Enrollment
12 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

allergy to cats